Literature DB >> 17352346

Clinical equipoise and treatment decisions in cervical spondylotic myelopathy.

Michael Benatar1.   

Abstract

OBJECTIVE: The primary objective of this study is to evaluate clinician attitudes towards the treatment of cervical spondylotic myelopathy (CSM) in order to determine whether clinical equipoise exists for a segment of this patient population. The secondary objective is to examine the factors that influence treatment decisions.
METHODS: Cross-sectional internet-based survey of neurologists, neurosurgeons and orthopedic surgeons.
RESULTS: Between 40-60% of respondents recommended surgery for (1) patients with minimal or no symptoms, but incidentally discovered increased T2 signal within the cervical cord on MRI, (2) patients with mild symptoms and indentation of the cervical cord but without increased T2 signal and (3) those with at least moderately severe clinical findings accompanied by MRI showing effacement of the thecal sac but without indentation of the cord or increased T2 signal. The severity of the radiological abnormalities most strongly influence treatment decisions.
CONCLUSIONS: We conclude that clinical equipoise does exist for certain groups of patients with CSM, suggesting that a randomized controlled trial could be performed in this population.

Entities:  

Mesh:

Year:  2007        PMID: 17352346     DOI: 10.1017/s0317167100005771

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  2 in total

Review 1.  Commentary : The value of intraoperative neurophysiological monitoring: evidence, equipoise and outcomes.

Authors:  R N Holdefer; S A Skinner
Journal:  J Clin Monit Comput       Date:  2016-08-01       Impact factor: 2.502

2.  Value of Surgery and Nonsurgical Approaches for Cervical Spondylotic Myelopathy: WFNS Spine Committee Recommendations.

Authors:  Jutty Parthiban; Oscar L Alves; Komal Prasad Chandrachari; Premanand Ramani; Mehmet Zileli
Journal:  Neurospine       Date:  2019-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.